Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Meningeal carcinomatosis
- Focus Adverse reactions
- Acronyms HIT
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.
- 07 Apr 2018 Results (n=19) of phase1 part of study assessing tolerability and efficacy of intrathecal trastuzumab administration for the treatment of patients with metastatic HER2-positive breast cancer, developing carcinomatous meningitis, were published in the European Journal of Cancer.
- 02 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2018.